PainChek Inks Landmark 20,000-Bed North America Deployment with Sabra Health Care REIT

Why It Matters

The agreement positions PainChek to capture a sizable share of the North American long‑term‑care market, leveraging regulatory approval to generate sustainable, reimbursable revenue. Success will determine whether the firm can turn rapid growth into profitability amid sizable operating losses.

Key Takeaways

• PainChek secures 20,000‑bed deployment across US and Canada
• Pricing $55‑75 per bed annually under perpetual contract
• FDA De Novo clearance enables CMS RTM reimbursement eligibility
• Sabra funds costs, reducing adoption barriers for long‑term care operators
• PainChek posted $1.7 M revenue, $4.7 M net loss H1 2025

Pulse Analysis

PainChek's partnership with Sabra Health Care REIT marks a watershed moment for the Australian‑based health‑tech firm, giving it a foothold in a market that houses roughly 20,000 long‑term‑care beds across the United States and Canada. By bundling the cost of its pain‑assessment platform into a per‑bed subscription of $55‑$75, PainChek aligns its pricing with the economics of large facilities while offering Sabra the ability to fund deployments on behalf of operators, a model that accelerates adoption and shortens sales cycles.

The deal is underpinned by recent regulatory milestones. In October 2025 the company secured FDA De Novo clearance for its Adult App, a prerequisite for classification as a medical device under CMS guidelines. This clearance unlocked eligibility for Remote Therapeutic Monitoring (RTM) reimbursement, allowing providers to claim recurring payments for remote pain‑assessment services. The RTM pathway is especially valuable in dementia care, where non‑verbal patients benefit from continuous monitoring, creating a durable revenue stream that can offset the high upfront costs of device rollout.

Financially, PainChek remains in a growth‑investment phase. Revenue climbed 5% to $1.7 million for the six months ended December 31, 2025, but the firm logged a $4.7 million net loss and burned $5.0 million in operating cash. The UK segment contributed an additional $152,000 in annual recurring revenue after adding 4,000 licences, underscoring the company’s ability to monetize new contracts. The key challenge now is translating regulatory clearance and the Sabra agreement into scalable commercial success while managing operating losses and the broader execution risk inherent in expanding a niche medical‑device platform.